Web Nerds

About maf2014

This author has not yet filled in any details.
So far maf2014 has created 115 entries.

Revlon Announces Completion of Elizabeth Arden Acquisition

NEW YORK – September 7, 2016 – Revlon, Inc. (NYSE: REV) is pleased to announce the successful completion of the Elizabeth Arden acquisition. The transaction creates a global beauty company with a strong portfolio of leading brands, including Revlon, Elizabeth Arden, Revlon ColorSilk, Revlon

September 7th, 2016|Press Center|

Deluxe Australia Boosts Focus on Growing Demand for OTT/Broadcast Services and Visual Effects; Winds Down Local Post-Production Services with Closure of DDP Studios and Stage One Sound

Deluxe Entertainment Services Group Inc. (Deluxe) confirmed today that the Company is focusing on growing its presence in Australia around its cloud-based playout, media asset management and media delivery services for film, television and broadcast, and its visual effects services. With this focus, Deluxe

September 5th, 2016|Press Center|

Scientific Games Announces Definitive Agreement to Acquire DEQ Systems

LAS VEGAS and LEVIS, QUEBEC – August 31, 2016 – Scientific Games Corporation (“Scientific Games” or the “Company”) and DEQ Systems Corp. (“DEQ”), today announced that they have entered into a definitive agreement (the “Agreement”) under which Scientific Games will acquire all of DEQ’s

August 31st, 2016|Press Center|

SIGA Announces Completion of Enrollment and Dosing in the Final Cohort of Phase III Study of TPOXX™ (tecovirimat)

NEW YORK – August 29, 2016 – SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced completion of enrollment and dosing in the second and final cohort of healthy

August 29th, 2016|Press Center|

vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes

HIGH POINT, NORTH CAROLINA – August 10, 2016 –vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced positive topline results from a placebo and active-comparator-controlled Phase

August 10th, 2016|Press Center|

AM General awarded $356 million contract to build 1,673 HMMWVs

SOUTH BEND, INDIANA– August 1, 2016 – AM General has been awarded a $356,213,318 contract to manufacture and deliver 1,673 HMMWVs to the U.S. Government for further delivery to the Afghanistan National Army and Police.

The contract calls on AM General to deliver 1,259 -M1151A1B1

August 1st, 2016|Press Center|

Deluxe Extends 4K/UHD Services to Facilitate HDR Content Management and Delivery

Deluxe Entertainment Services Group Inc. (Deluxe) announced today that the company’s multiscreen and Over-the-Top (OTT) media management and delivery platform, Deluxe OnDemand™, now provides key workflow capabilities to enable distributors and programmers to quickly and easily participate in the next wave of 4K/UHD with

April 14th, 2016|Press Center|

Deluxe Provides Industry-First Delivery of Live 4K Video Across the Globe Using the Public Internet

LOS ANGELES and LONDON – March 29, 2016 – Deluxe Entertainment Services Group Inc. (Deluxe) announced today that its MediaCloud platform has successfully broadcast live 4K video between Europe and North America at over 50Mbps using the public Internet, delivering 100% uptime and availability.

March 29th, 2016|Press Center|

Revlon Names Fabian T. Garcia as its President and Chief Executive Officer

NEW YORK–March 28, 2016–Revlon, Inc. (NYSE: REV) announced today that its Board of Directors elected Fabian T. Garcia as Revlon’s President and Chief Executive Officer, effective April 15, 2016. Fabian was also appointed to serve as a member of Revlon’s Board of Directors,

March 28th, 2016|Press Center|

vTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes

TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential

Topline results are expected at the end of 2016

HIGH POINT, N.C.– January 21, 2016 – vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company
engaged in the discovery and development of new orally administered treatments

January 21st, 2016|Press Center|